Intended for healthcare professionals


Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years

BMJ 2024; 386 doi: (Published 08 July 2024) Cite this as: BMJ 2024;386:q1511

Linked Opinion

Broken beyond repair: self regulation of industry payments to clinicians and hospitals

  1. Elisabeth Mahase
  1. The BMJ

Drug company Novo Nordisk has been reprimanded by the UK pharmaceutical regulator after it admitted failing to disclose around £7.8m in payments to 150 recipients including doctors, patients, journalists, and healthcare organisations over a three year period.12

In a voluntary admission Novo Nordisk informed the Prescription Medicines Code of Practice Authority (PMCPA) that between 2020 and 2022 it had failed to disclose around 500 payments because of problems with its vendor tagging system. PMCPA is the self-regulatory body that administers the Association of the British Pharmaceutical Industry’s (ABPI) code of …

View Full Text

Log in

Log in through your institution


* For online subscription